Immunomedics, Inc. (IMMU) Announces Third Quarter Fiscal 2013 Results and Clinical Program Developments
5/9/2013 10:19:31 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
MORRIS PLAINS, N.J., May 8, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported financial results for the third quarter ended March 31, 2013. The Company also highlighted recent key developments and planned activities for its clinical pipeline.
Help employers find you! Check out all the jobs and post your resume.